Izumerogant

Modify Date: 2024-04-06 17:56:48

Izumerogant structure	Common Name	Izumerogant
	CAS Number	2299252-72-3	Molecular Weight	495.86
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₂H₁₈ClF₄N₅O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Izumerogant

Izumerogant is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM[1][2].

Name	Izumerogant

Description	Izumerogant is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> ROR Research Areas >> Others
References	[1]. F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14. [2]. WHO Drug Information-World Health Organization (WHO).

Description

Izumerogant is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM[1][2].

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> ROR

Research Areas >> Others

References

[1]. F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14.

[2]. WHO Drug Information-World Health Organization (WHO).